LAJIN ENT (08172) announced that on December 4, 2025, the company received a letter from the Hong Kong Stock Exchange (HKEX) outlining the guidance for resuming trading of its shares. According to the resumption requirements, the company must: demonstrate compliance with GEM Listing Rule 17.26; and disclose all material information to the market to enable shareholders and investors to assess its financial condition. The company's shares will remain suspended from trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.